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Introduction: Systemic connective tissue diseases are specific in nature and usually need to 
be treated with long-term aggressive treatment consisting of a higher number of drugs. A need 
for treatment of other, sometimes related conditions is common as well. The higher number of 
drugs, the presence of unpleasant side effects and complicated dosing schedules may create a 
suitable environment for development of drug related problems, such as drug interactions and 
patient drug compliance.  
Objectives: The purpose of the work is to analyze two drug related problems (drug 
interactions and drug compliance) in the area of pharmacotherapy of systemic connective 
tissue diseases. The work is aimed to review interactions of glucocorticosteroids, 
immunosuppressants and antimalarial drugs with common medicines used in practice, 
to analyze drug compliance and its potential risk factors in systemic scleroderma 
and to summarize existing knowledge about drug compliance in rheumatoid arthritis.  
Methods: Drug interactions were investigated during a systematic literature review using the 
following sources: Micromedex, PubMed, Medline, InfoPharm Compendium of Drug 
Interactions, Summary of product characteristics and reference lists of the retrieved 
publications. When searching, the following combinations of key words were used: 
interactions, drug interactions and names of particular interacting drugs. For each interaction, 
its nature, mechanism, onset and clinical severity were noted, documentation quality was 
rated, and recommendations for clinical practice were formulated. To evaluate drug 
compliance in patients with systemic scleroderma an experimental observational study was 
conducted in rheumatic center in Hradec Králové between January 2010 and June 2011. Data 
was obtained during structured interviews with patients and from medical records. Drug 
compliance in rheumatoid arthritis was assessed by literature review using PubMed. The 
following combinations of key words were used: „rheumatoid arthritis“ and „drug 
compliance“, „drug adherence“, „compliance rate“, „adherence rate“, „treatment compliance“ 
or „treatment adherence“.  
Results: Of more than 300 discovered drug interactions only 20 interactions were identified to 
be clinically important, moderate to very severe and potentially occurring by treatment of 
systemic connective tissue diseases. Interactions were found for the following antirheumatic 
drugs: prednisone, methylprednisolone, antimalarial drugs, methotrexate, leflunomide, 
azathioprine, cyclosporine, cyclophosphamide, sulphasalazine, penicillamine. The interaction 
between glucocorticosteroids and warfarin was elaborated in details in a separate work 
because of the frequent occurrence of this combination in practice also outside the area of 
rheumatology. In the evaluated group of patients with systemic scleroderma the mean drug 
compliance score measured by a specific questionnaire was 75.4 (the possible range 0 - 100) 
and the satisfactory compliance level (≥ 80) was reached in 41.5 % of patients. No significant 
predictor of compliance was found in the study. A review of drug compliance in rheumatoid 
arthritis revealed a great diversity of studies in their results and conclusions. Compliance rate 
measured in studies ranged from 30 to 98 and only in three of 17 included studies the detected 
compliance was lower than the average stated by the World Health Organization.   
Conclusion: In the thesis two drug related problems accompanying pharmacotherapy 
of systemic connective tissue diseases were analyzed. Important interactions of classical 
antirheumatic drugs were summarized, drug compliance and its predictors were tested 
in systemic scleroderma patients and present knowledge of drug compliance in rheumatoid 
arthritis was reviewed. The work is open to all healthcare professionals who care 
for rheumatic patients and it should help to minimize risks of therapy.  
 
